Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UltraMeal Plus 360
- Development stage
- Unknown
- Lead developer
- MetaProteomics LLC
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
UltraMeal Plus 360 is a medical food formulated by Metagenics specifically designed for the dietary management of conditions associated with metabolic syndrome, including hyperlipidemia, hypertension, and insulin resistance. The product features a unique combination of soy protein and plant sterols (phytosterols) to support healthy lipid profiles, alongside proprietary Selective Kinase Response Modulators (SKRMs) in the form of rho iso-alpha acids (RIAA) derived from hops and proanthocyanidins (PACs) derived from grape seed. These SKRMs are intended to modulate insulin signaling pathways and inflammatory markers like NF-kappaB. Clinical studies have demonstrated that this combination, when used in conjunction with a low-glycemic-load diet, is more effective than diet alone in improving markers of cardiovascular risk and metabolic health.
- Brand names
- UltraMeal Plus 360
- Other names
- soy protein + phytosterols + rho iso-alpha acids + proanthocyanidins
02
Targets
ESR2 (ERβ)LDLR (Low-density lipoprotein receptor)NPC1L1 (Niemann-pick C1-Like 1 transporter)NF-κB
Beyond the preview
Go deeper on UltraMeal Plus 360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UltraMeal Plus 360.